The project plan outlines key operational enhancements, development of specialization areas, and support for new workforce development initiatives that will enable our GMP cell manufacturing facility be a key component of the new CIRM Cell and Gene Therapy Manufacturing Network. Support for this project will enable our facility to expand our capabilities and workforce development to better provide cell and gene therapy products for patients in California with otherwise untreatable or incurable diseases. Additionally, we will be better able to work with both California academic groups and biotechnology companies to support manufacturing of GMP cell therapies, as is much needed for both pre-clinical studies and early-stage clinical trials.